SCHEMBL10219552

SCHEMBL10219552

COc1cccc(Nc2ccc(-c3nc4ccccc4o3)cc2[N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
MAPT P10636 5/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
HPGD P15428 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
LMNA P02545 2/20 0.54
CASP3 P42574 1/20 0.54
PTPN2 P17706 2/20 0.52
PTPN1 P18031 2/20 0.52
PTPN5 P54829 2/20 0.52
HSPD1 P10809 1/20 0.52
HSPE1 P61604 1/20 0.52
P2RY14 Q15391 2/20 0.52
AKR1B10 O60218 1/20 0.49
AKR1B1 P15121 1/20 0.49
AKR1C4 P17516 1/20 0.49
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2687425 0.90 PTPN2 (0.57) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL10219550 0.85 NPC1 (0.55) MAPTNPC1RAB9AHPGDSMN1; SMN2
SCHEMBL2689906 0.83 PTPN2 (0.54) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL10219564 0.83 PTPN2 (0.54) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL6683075 0.78 NPC1 (0.68) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL26906360 0.77 MAPT (0.75) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL2687689 0.77 MAPT (0.58) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL2687092 0.77 POLB (0.56) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL10219545 0.77 MMP2 (0.55) MEN1KMT2AMAPTNPC1RAB9A
SCHEMBL2687950 0.76 TP53 (0.59) MEN1KMT2AMAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
US-8829035-B2 Agent for treatment or prevention of diseases associated with activity of neurotrophic factors SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-09-09 US disclosed
EP-2436683-B1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL CO (JP) 2014-05-14 EP disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115856-A1 AGENT FOR TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH ACTIVITY OF NEUROTROPHIC FACTORS BDNF, NGF, NTRK2 MEN1 2349/4885KMT2A 4282/4885MAPT 2988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.